TY - JOUR
T1 - Oral-only antibiotics for bone and joint infections in children
T2 - study protocol for a nationwide randomised open-label non-inferiority trial
AU - Bybeck Nielsen, Allan
AU - Borch, Luise
AU - Damkjaer, Mads
AU - Glenthøj, Jonathan Peter
AU - Hartling, Ulla
AU - Hoffmann, Thomas Ulrik
AU - Holm, Mette
AU - Helleskov Rasmussen, Annett
AU - Schmidt, Lisbeth Samsø
AU - Schmiegelow, Kjeld
AU - Stensballe, Lone Graff
AU - Nygaard, Ulrikka
AU - Local Investigators
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2023/6
Y1 - 2023/6
N2 - INTRODUCTION: Children with bone and joint infections are traditionally treated with intravenous antibiotics for 3-10 days, followed by oral antibiotics. Oral-only treatment has not been tested in randomised trials. METHODS AND ANALYSIS: Children (3 months to 18 years) will be randomised 1:1 with the experimental group receiving high-dose oral antibiotics and the control group receiving intravenous antibiotics with a shift in both groups to standard oral antibiotics after clinical and paraclinical improvement. Children in need of acute surgery or systemic features requiring intravenous therapy, including septic shock, are excluded. The primary outcome is defined as a normal blinded standardised clinical assessment 6 months after end of treatment. Secondary outcomes are non-acute treatment failure and recurrent infection. Outcomes will be compared by a non-inferiority assumption with an inferiority margin of 5%. ETHICS AND DISSEMINATION: The trial has the potential to reduce unnecessary hospitalisation and use of intravenous antibiotics in children with bone or joint infections. Due to the close follow-up, exclusion of severely ill children and predefined criteria for discontinuation of the allocated therapy, we expect the risk of treatment failure to be minimal. TRIAL REGISTRATION NUMBER: NCT04563325.
AB - INTRODUCTION: Children with bone and joint infections are traditionally treated with intravenous antibiotics for 3-10 days, followed by oral antibiotics. Oral-only treatment has not been tested in randomised trials. METHODS AND ANALYSIS: Children (3 months to 18 years) will be randomised 1:1 with the experimental group receiving high-dose oral antibiotics and the control group receiving intravenous antibiotics with a shift in both groups to standard oral antibiotics after clinical and paraclinical improvement. Children in need of acute surgery or systemic features requiring intravenous therapy, including septic shock, are excluded. The primary outcome is defined as a normal blinded standardised clinical assessment 6 months after end of treatment. Secondary outcomes are non-acute treatment failure and recurrent infection. Outcomes will be compared by a non-inferiority assumption with an inferiority margin of 5%. ETHICS AND DISSEMINATION: The trial has the potential to reduce unnecessary hospitalisation and use of intravenous antibiotics in children with bone or joint infections. Due to the close follow-up, exclusion of severely ill children and predefined criteria for discontinuation of the allocated therapy, we expect the risk of treatment failure to be minimal. TRIAL REGISTRATION NUMBER: NCT04563325.
KW - clinical trial
KW - oral medicine
KW - paediatric infectious disease & immunisation
KW - patient-centered care
U2 - 10.1136/bmjopen-2023-072622
DO - 10.1136/bmjopen-2023-072622
M3 - Journal article
C2 - 37263683
AN - SCOPUS:85160967224
SN - 2044-6055
VL - 13
JO - BMJ Open
JF - BMJ Open
IS - 6
M1 - e072622
ER -